Trail Making Test performance in early abstinence from methamphetamine: human evidence for a drug-associated Parkinsonian-like phenotype - Top-Institutions - MDSpire

Trail Making Test performance in early abstinence from methamphetamine: human evidence for a drug-associated Parkinsonian-like phenotype

  • By

  • Alexandru Mihai Dumitrescu

  • M. Frances Vest

  • Annette E. Fleckenstein

  • James C. Patterson

  • Christina Ledbetter

  • Nicholas E. Goeders

  • Jennifer M. Loftis

  • Elliot Thompson

  • Katelyn Lofton

  • Kevin S. Murnane

  • March 23, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Addiction Medicine
    • Neuropsychology

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Addiction Medicine
    • Neuroimaging

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Addiction Psychiatry
    • Cognitive Neuroscience

  • #4

    University of Washington
    University of Washington

    Seattle, WA

    Key Differentiators

    • Neurology
    • Addiction Medicine
    • Neuropsychology

  • #5

    Columbia University Irving Medical Center
    Columbia University Irving Medical Center

    New York, NY

    Key Differentiators

    • Neurology
    • Addiction Psychiatry
    • Neuropsychology

Original Source(s)

Trail Making Test performance in early abstinence from methamphetamine: human evidence for a drug-associated Parkinsonian-like phenotype

  • by Alexandru Mihai Dumitrescu, M. Frances Vest, Annette E. Fleckenstein, James C. Patterson, Christina Ledbetter, Nicholas E. Goeders, Jennifer M. Loftis, Elliot Thompson, Katelyn Lofton, Kevin S. Murnane

  • March 23, 2026

Related Content

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes

Intermittent Theta-Burst Stimulation for Depressive Symptoms in Parkinson Disease: A Randomized Clinical Trial